Also, flow cytometry from PBMCs isolated from 31 melanoma patients treated with anti-PD-1 or anti-PD-1 plus an anti-CTLA-4 combination revealed that responders showed an increase in the CD8+ Tem subset after three weeks of treatment [33]. This evidence concerns the gene CD8A and melanoma.